<DOC>
	<DOCNO>NCT00806286</DOCNO>
	<brief_summary>The study safety Phase 2 portion . In safety portion study , subject metastatic non-small cell lung cancer treat study drug ( CS-7017 ) combination carboplatin paclitaxel evaluate safety . In Phase 2 portion study , subject receive study drug ( CS-7017 ) placebo combination carboplatin paclitaxel evaluate effectiveness safety . The study find add CS-7017 carboplatin paclitaxel safe improve progression free survival subject metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>Study Carboplatin/Paclitaxel With Without Investigational Drug ( CS-7017 ) Subjects With Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Efatutazone</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm metastatic ( stage IV ) NSCLC significant pleural effusion pleural involvement tumor Age great equal 18 year Adequate organ bone marrow function Any prior systemic therapy NSCLC Major surgical procedure investigational agent within 4 week study enrollment Need concomitant use thiazolidinediones study History follow condition within 6 month prior initiate study treatment : Diabetes mellitus require treatment insulin sulfonylurea TZDs agent ; Myocardia infarction significant impairment cardia function ; Malabsorption syndrome , chronic diarrhea , inflammatory bowel disease partial bowel obstruction ; Clinically active brain metastasis , uncontrolled seizure disorder ; spinal cord compression carcinomatous meningitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>